These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18086412)

  • 1. Development of protease inhibitors and the fight with drug-resistant HIV-1 variants.
    Mitsuya H; Maeda K; Das D; Ghosh AK
    Adv Pharmacol; 2008; 56():169-97. PubMed ID: 18086412
    [No Abstract]   [Full Text] [Related]  

  • 2. Resistance to protease inhibitors.
    Kuritzkes DR
    J HIV Ther; 2002 Nov; 7(4):87-91. PubMed ID: 12733606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-resistance within the protease inhibitor class.
    Race E
    Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
    [No Abstract]   [Full Text] [Related]  

  • 4. No inherent association between minor mutations in HIV protease at baseline and selection of the L90M mutation at the time of the first virological failure.
    Brumme CJ; Harrigan PR
    J Infect Dis; 2005 May; 191(10):1778-9; author reply 1779-80. PubMed ID: 15838807
    [No Abstract]   [Full Text] [Related]  

  • 5. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876
    [No Abstract]   [Full Text] [Related]  

  • 6. Evolution of protease and reverse transcriptase inhibitor resistance-associated mutations in HIV-1-infected protease inhibitor-treated patients with persistent low viraemia.
    Duval X; Descamps D; Breton G; Darmon S; Ecobichon JL; Delarue S; Peytavin G; Leport C; Vildé JL; Brun-Vézinet F
    Antivir Ther; 2005; 10(1):197-9. PubMed ID: 15751779
    [No Abstract]   [Full Text] [Related]  

  • 7. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 8. Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies.
    Bartonová V; Král V; Sieglová I; Brynda J; Fábry M; Horejsí M; Kozísek M; Sasková KG; Konvalinka J; Sedlácek J; Rezácová P
    Antiviral Res; 2008 Jun; 78(3):275-7. PubMed ID: 18329737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of HIV protease inhibitor resistance in treatment-naive populations in the united states.
    Hicks C
    AIDS Read; 2005 Dec; 15(12):683-6, 689-90. PubMed ID: 16355598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
    de Mendoza C; Garrido C; Corral A; Zahonero N; Soriano V
    AIDS; 2008 Jan; 22(2):311-3. PubMed ID: 18097236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detectable viral loads and slow development of resistance.
    Gadd C
    IAPAC Mon; 2005 Oct; 11(10):295-6. PubMed ID: 16673496
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus protease inhibitors.
    Kline MW
    Pediatr Infect Dis J; 2003 Dec; 22(12):1085-7. PubMed ID: 14688570
    [No Abstract]   [Full Text] [Related]  

  • 15. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
    Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
    Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological exposure and the development of drug resistance in HIV.
    Hoetelmans R
    Antivir Ther; 2001; 6 Suppl 2():37-47. PubMed ID: 11678477
    [No Abstract]   [Full Text] [Related]  

  • 17. Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects.
    Paulsen D; Elston R; Snowden W; Tisdale M; Ross L
    J Antimicrob Chemother; 2003 Sep; 52(3):319-23. PubMed ID: 12917233
    [No Abstract]   [Full Text] [Related]  

  • 18. New drugs for old.
    Winston A; Stebbing J
    J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid detection of drug resistant HIV -1 to reverse transcriptase and protease inhibitors in HIV-infected patients receiving highly active antiretroviral therapies.
    Yu M; Kabat W; Wang J
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2000 Dec; 14(4):325-9. PubMed ID: 11471017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients.
    Paolucci S; Baldanti F; Zavattoni M; Comolli G; Labò N; Menzo S; Clementi M; Gerna G
    J Antimicrob Chemother; 2003 Jan; 51(1):135-9. PubMed ID: 12493798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.